SCHEMBL25355441

SCHEMBL25355441

COc1cc(C=O)cnc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.51
ALDH1A1 P00352 12/20 0.50
TSHR P16473 1/20 0.50
HPGD P15428 3/20 0.46
TRIM24 O15164 1/20 0.46
ALDH5A1 P51649 1/20 0.46
ABAT P80404 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TRIM33 Q9UPN9 1/20 0.46
MAPT P10636 6/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29936033 1.00 FDPS (0.51) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL2698927 0.81 FDPS (0.51) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL29950972 0.81 FDPS (0.51) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL23904966 0.80 ALDH1A1 (0.46) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL29954529 0.79 FDPS (0.50) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL16564249 0.79 ALDH1A1 (0.53) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL13723899 0.79 FDPS (0.50) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL22322334 0.79 ALDH1A1 (0.50) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL10131337 0.79 FDPS (0.50) FDPSALDH1A1TSHRHPGDTRIM24
SCHEMBL29954141 0.79 ALDH1A1 (0.50) FDPSALDH1A1TSHRHPGDTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114374-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2025-04-10 US disclosed
WO-2023122000-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. (US) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114374-A1 BCL-2 INHIBITORS BCL2, BCL2L1, BCL2L10 FDPS 3779/4885ALDH1A1 3831/4885TSHR 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.